EPHA2 and pancreatic neoplasm: Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. (China) is currently conducting a Phase I trial, which is a single-center, single-arm, open-label study aimed at evaluating the safety and efficacy of CAR-T cell therapy targeting EphA2 expressed on various solid tumors, including pancreatic cancer (NCT05003895).